Menu Close

Author: WorkCompAcademy

May 27, 2019 News Podcast


Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories: States Pursue Strategies Against Purdue Bankruptcy, USC Surgeon Faces Insurance Fraud Lawsuit, Disability Attorney/Serial Plaintiff Indicted for Tax Fraud, Chiropractor Convicted of Insurance Fraud, Welding Fumes Linked to Lung Cancer, Diabetic Drug Greatly Reduces Fibromyalgia Pain, Startup Disrupts Pharmacy Business Model, WC Drug Costs and Utilization Improved in 2018, Officials Claim Purdue Misled World Health Organization, CompWest Announces California Expansion.

School Officials Convicted for SJDB Voucher Fraud

Two defendants entered no contest pleas to attempting to defraud multiple insurers of approximately $120,000 by having students sign over their Supplement Job Displacement vouchers and collecting the money without providing required vocational training.

Salvador Franco, Jr., 42, of Downey and Mirella Flores, 45, of Paramount were each charged with one felony count of conspiring to commit a crime, 18 felony counts of making a fraudulent statement to obtain or deny compensation, and 18 felony counts of fraudulent claims. On May 24, 2019, both defendants accepted a court offer and pled no contest to all counts.

Franco and Flores were immediately sentenced to three years of formal probation and ordered to pay $88,000 in restitution to insurers and $62,000 in investigative costs to the California Department of Insurance. The defendants were also sentenced to 90 days in Orange County Jail, however this was stayed pending the completion of 275 hours of community service by Franco and 250 hours by Flores.

Between 2015 and 2017, Franco and Flores participated in an alleged Supplemental Job Displacement Voucher Fraud scheme involving the Technical School, Inc., doing business as Technical College, Inc., and Graduates Do Succeed Institute, doing business as GDS Institute. Franco was a 20 percent owner and a Director of Technical College as well as its Chief Financial Officer. He was also the Chief Financial Officer of GDS Institute. Flores was an employee for both schools.

The defendants conspired and offered to provide workers’ compensation claimants with either at-home or off-site training for a few hours a week along with work related materials such as a computer. In exchange, claimants were expected to sign over their Supplement Job Displacement Vouchers that were valued between $4,000 and $10,000. Other students were offered a monetary payment in exchange for signing over their vouchers and not attending any training.

The enrollment materials allegedly sent to insurers for payment on the vouchers, however, vastly misrepresented the training that the claimants were going to receive. Instead of listing the at-home training, the provision of supplies, or the kickbacks to the students, defendants described the training as being several hundred hours in length, requiring full-time (40 hours per week) attendance at one of the schools’ campuses.

Compwest Insurance Company was alerted to the alleged fraudulent scheme by a claimant living in Orange County who did not receive the promised in-home training from Technical College. Compwest then notified both OCDA and the California Department of Insurance, who agreed to jointly investigate the complaint. Shortly thereafter, the Los Angeles District Attorney’s Office joined the investigation.

Deputy District Attorney Steven Schriver of the Insurance Fraud Unit prosecuted this case.

Wellness Program Regulations Delayed – Again!

Employee wellness seems like a good thing. Employers, employees and taxpayers all benefit when citizens are healthier. There would be benefits for those involved in workers’ compensation claims. So government sought to allow incentives for wellness. What seemed like a simple concept got very complicated, involving layers of federal and state law, and regulations, and court litigation.

Fast forward to 2019, regulatory battles, and delays over wellness programs continues to get more complicated.

Pushing its deadline back for the second time, the Equal Employment Opportunity Commission (EEOC) recently announced that it plans to issue amended regulations related to incentivizing participation in employer-sponsored voluntary wellness programs under the Americans with Disabilities Act (ADA) and the Genetic Information Nondiscrimination Act (GINA) by the end of this year.

The EEOC finalized wellness program rules in May 2016, only to have a federal district court vacate portions of the rules in August 2017.

The court required the EEOC to revise the incentive-limit portion of the rules (which stated that employers could use an incentive or penalty of up to 30 percent of the cost of self-only coverage to encourage participation in an employer-sponsored wellness program without rendering the program “involuntary” in violation of federal statutes) by January 1, 2018.

Right before the January 1 deadline was set to expire, the EEOC scrapped the portion of its final rules related to wellness program incentives. In its regulatory agenda published in Fall 2018, the EEOC said that it would publish new regulations by June 2019. However, with that deadline approaching, the agency once again moved the goal post.

Part of the EEOC’s holdup with issuing new rules on wellness program incentives was that the Commission – comprised of presidentially appointed members – was awaiting the confirmation of two members (including a chair) and a general counsel.

However, within a matter of days following this month’s swearing-in of new EEOC Chair Janet Dhillon, the agency unveiled its spring regulatory agenda for 2019 that included an update on the wellness program rules.

The agency is developing a notice of proposed rulemaking to address wellness programs under both the ADA and GINA in response to the court’s August 2017 ruling. The agenda also indicated completion by December 2019.

During her confirmation hearing, Dhillon testified that she would rewrite the regulations to comply with both congressional intent and the court’s August 2017 opinion in AARP v. EEOC.

Legal experts believe new regulations will likely go to great lengths to encourage participation in wellness programs – including possibly raising the 30 percent cap under the old rules – as well as provide greater clarity on where incentives stand with respect to ADA and GINA compliance..

Apportionment Limits Passed by CA Senate

A few recent decisions have enhanced the ability of employers to obtain apportionment of permanent disability. However the court successes may be short lived as a new proposed law is rapidly gaining momentum in the California Legislature to limit or water down apportionment law adopted in 2004 by S.B. 899.

In April 2017, the Court of Appeal published its decision in the City of Jackson v WCAB (Rice) which confirmed apportionment to genetic factors. Christopher Rice was a police officer who suffered a spine injury. A PQME found that genetic factors were significant factors in his permanent impairment. The Court of Appeal reversed the WCAB which refused to allow apportionment to genetics.

In December 2018, the Court of Appeal published its decision in City of Petaluma v WCAB and Aaron Lindh. In that case a PQME concluded that 85 percent of his disability was due to a previously asymptomatic, underlying condition. The ALJ, however, rejected apportionment and reconsideration was denied by the WCAB. The Court of Appeal reversed, and granted apportionment finding that the requirement that the asymptomatic preexisting condition will, in and of itself, naturally progress to disable the claimant. was “the law prior to 2004” and is no longer a requirement for apportionment to an underlying condition.

And recent panel decisions show that the WCAB seems to be ruling in conformity with these decisions. In the 2018 WCAB panel decision in Schuy v City of Yuba, the WCJ rejected the opinion of and AME that said that Marilyn Schuy’s continuous trauma low back injury was 50% caused by progression of a degenerative back condition. A WCAB panel reversed citing the Court of Appeal City of Jackson v Rice, and the provisions of Labor Code sections 4663 & 4664(a) which allows apportionment to non industrial causation.

This year the California Legislature again introduced legislation poised to limit apportionment in several ways with SB 731. The proposed law adds a sentence to LC 4663 (c) “The approximate percentage of the permanent disability caused by other factors shall not include consideration of race, religious creed, color, national origin, age, gender, marital status, sex, sexual identity, sexual orientation, or genetic characteristics.”

SB 731 has been passed by the California Senate on 5/19/2019, and is now being heard in the State Assembly as of 5/22/2019. Clearly the proposed law will nullify City of Jackson v WCAB (Rice) since apportionment in that case was based on genetics. Apportionment in the Schuy case which is based upon a degenerative condition is arguably based upon “age” as well, a factor to be outlawed if the bill becomes law.

Similar bills were passed by the legislature and then vetoed by Governors Arnold Schwarzenegger and Jerry Brown for many years. It is likely that SB 731 will again be passed by the legislature. It is not clear what response Governor Gavin Newsom will have if itis passed.

Money Does Not Buy Better Comp Outcomes

A new study published by the Workers’ Compensation Research Institute addresses a long-standing policy debate about the role of workers’ compensation prices in outcomes of injured workers, specifically what happens to outcomes of injured workers when prices increase or decrease.

The study is the first to combine surveys of injured workers with claims data to examine the relationship between workers’ compensation prices for medical services and the outcomes that workers experience after a work-related injury.

Researchers determined that when the price of physician services increases relative to group health rates, injured workers report fewer problems getting the care they want but no significant improvement in physical function or speedier return to work.

In areas where workers’ comp paid less than group health, WCRI found increasing the price to approximately the group health rate led to a small increase in the duration of temporary disability, but little changes in measures of access to care, recovery of physical functioning and speed of return to work.

In areas where workers’ comp already paid more than group health, price increases led to fewer concerns about access to care, faster time to non-emergency visits with physicians, and more care provided to injured workers, but little change in measures of recovery of physical functioning, speed of return to work and duration of temporary disability.

“While prices are related to measures of access to medical care and the nature of medical care provided, changes in these measures when prices increase are not material enough to result in improved recovery and faster return to work,” the report says.

The Insurance Journal reported that Steve Cattolica, a lobbyist for the California Workers’ Compensation Services Association, which represents medical providers, said he isn’t surprised that research shows no correlation between increased medical prices and better outcomes for injured workers. He said there are numerous variables in any workers’ compensation system: Factors such as the method of utilization review, how well physicians communicate with payers and the administrative hurdles that each system presents to providers can have substantially more impact than prices on worker outcomes.

Cattolica said in the California workers’ compensation system about half the money paid out goes toward running the administrative system; everything from attorneys, to bill reviewers to claims adjusters.

“The elephant in the room is how that care is actually provided,” Cattolica said. “There’s ample proof that the industrial medical complex – you know like, Eisenhower’s industrial-military complex – has overwhelmed the cost of administering and providing benefits.”

One Defendant Remains in First Opioid Trial

Teva Pharmaceutical Industries Ltd.’s move to pay $85 million to resolve an Oklahoma lawsuit alleging it and other drugmakers illegally marketed opioid painkillers, fueling a public health crisis, leaves Johnson & Johnson in the uncomfortable position of being the state’s sole target in the first opioid lawsuit set to start on May 28.

Bloombert reports that the settlement with Oklahoma’s attorney general, announced Sunday, came nearly on the eve of trial and followed a $270 million deal by Purdue Pharma LP in March to resolve identical claims over the marketing of its opioid-based OxyContin painkiller. The state alleged the three companies duped doctors into prescribing the powerful medications for unapproved ailments, causing fatal overdoses and drug-addiction woes.

Oklahoma is seeking at least $10 billion in damages and penalties for current and future outlays tied to the opioid epidemic. The trial is slated to be the first test of public-nuisance laws against opioid manufacturers and distributors. At least 42 states and more than 1,900 municipalities also have sued companies in the industry, demanding billions of dollars in damages.

J&J — known for being loath to settle mass-tort litigation at the early stages — so far hasn’t cut an out-of-court deal to end the case, set to start May 28. Oklahoma Attorney General Mike Hunter has tagged the company as the “kingpin” of the opioid crisis because it once sold its own version of opioid painkillers as well as the active ingredient.

Andrew Wheatley, a spokesman for J&J and its Janssen unit, said Sunday the drugmaker was ready to defend itself at trial from Oklahoma’s claims that its painkillers caused a public nuisance in the state. Hunter contends J&J’s illegal marketing created a nuisance that forced the state to spend hundreds of millions of dollars to address the societal fall-out of opioid-related overdoses and addictions.

“We disagree with the state’s overly expansive theories of public nuisance law, which should not apply in this situation,” Wheatley said in an emailed statement. “At the same time, as with all litigation, if an appropriate resolution is possible that avoids the expense and uncertainty of a trial, we are always open to that option.”

There may be other settlements later this year as the focus on opioid litigation shifts to Cleveland, where a federal judge has set two test trials for October to allow juries to consider public-nuisance claims over drug-marketing campaigns, said Carl Tobias, a University of Richmond law professor who teaches as product-liability cases.

U.S. District Judge Dan Polster is overseeing more than 1,900 suits filed by U.S. cities and counties seeking recoup tax dollars spent fighting the opioid epidemic. Polster unsuccessfully sought to push the companies and local governments into settling and then set the test trials to get the case moving.

FDA Approves World’s Most Expensive Drug

The Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most expensive drug in the world.

Novartis is pricing Zolgensma at $2.125 million, or an annualized cost of $425,000 per year for five years, the company said.

Launching Zolgensma will be a big test for Novartis and CEO Vas Narasimhan, now two years on the job. Shareholders expect the gene therapy to deliver blockbuster sales to justify the $8.7 billion that Novartis spent to acquire it last year.

To achieve commercial success, Novartis must persuade doctors who treat SMA patients that the muscle-preserving benefits from a one-time injection of Zolgensma will be durable. Complex payment and insurance reimbursement arrangements required for expensive gene therapies need to be handled deftly.

Novartis is likely to face backlash from critics who believe charging millions of dollars for any medicine – no matter how effective – renders it unaffordable for a healthcare system already under financial stress.

There’s also competition. Spinraza, approved in late 2016 and sold by Biogen, has already been used to successfully treat thousands of patients with severe and milder forms of SMA. The drug requires regular spinal infusions costing $750,000 in the first year and $375,000 annually thereafter, for life. Sales last year totaled $1.7 billion. Zolgensma may be more convenient than Spinraza, but Roche is developing a daily pill for SMA called risdiplam that could reach the market in 2020.

The FDA approved Zolgensma to treat children under 2 diagnosed with SMA, regardless of genetic mutation. In its pivotal clinical trial and an ongoing clinical trial, a majority of the infants and young children injected once with Zolgensma remained alive, could breathe on their own, and showed improvements in motor milestones like being able to sit up without support.

Zolgensma “is markedly better than any other therapy out there, particularly in the clinical trials of type 1 that we’ve released,” Narasimhan told STAT in a recent interview. “Clearly, parents will know right away that this is a medicine that performs extremely, extremely well in these infants and has this kind of marked effect on their well-being.”

In its announcement, acting FDA Commissioner Ned Sharpless said the approval marks “another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases.”

Disability Attorney/Serial Plaintiff Indicted for Tax Fraud

The Justice Department’s Tax Division announced that a federal grand jury returned an indictment against attorney Scott Norris Johnson, 57, of Carmichael, charging him with three counts of making and subscribing a false tax return.

Johnson is known to sue small businesses citing minor ADA infractions, and based on the law, he can collect thousands of dollars in violations and recoup his own attorney’s fees. He almost always settles for tens of thousands of dollars.

According to the indictment, Johnson owned and operated Disabled Access Prevents Injury Inc. (DAPI), a legal services corporation. First using DAPI, and later using a law firm, Johnson filed thousands of lawsuits in the Eastern District of California and elsewhere. Johnson named himself as the plaintiff in the lawsuits and made claims under the Americans with Disabilities Act of 1990, the California Disabled Persons Act, and the California Unruh Civil Rights Act.

The East Bay Times reported that In December 2015, attorney Catherine Corfee, who often represents small businesses sued by Johnson, said she received an email from a federal prosecutor that there was a criminal grand jury probe into Johnson’s “treatment of settlement proceeds for ADA lawsuits.”

She recounted more than a decade opposing Johnson in court and how he would try to add physical injury wording to the settlements despite not alleging any such damages in the original complaint.

“I have refused to allow the words ’caused injury’ to make sure he pays his taxes,” Corfee said.

“I’m not going to participate in tax fraud,” she said. “Not one of my cases did I ever need to request medical records. If you don’t allege (physical injuries) in the lawsuit, then why settle for it?”  But, she said, other attorneys and defendants may not be as careful when finalizing their settlements.

Under the Small Business Job Protection Act of 1996, payments related to lawsuit settlements or awards are taxable unless they were paid on account of personal physical injury or physical sickness. Johnson, however, allegedly materially underreported the taxable income he received from lawsuit settlements and awards on his income tax returns for tax years 2012, 2013, and 2014. By understating his income on his tax returns, Johnson and DAPI paid little to no income tax for tax years 2012, 2013 and 2014.

This case is the product of an investigation by the Internal Revenue Service Criminal Investigation. Assistant U.S. Attorney Katherine T. Lydon and Trial Attorney Tim Russo of the Tax Division are prosecuting the case.

Officials Claim Purdue Misled World Health Organization

Vice Chair of the Democratic Caucus Congresswoman Katherine Clark  and Congressman Hal Rogers, co-founder and co-chairman of the Congressional Caucus on Prescription Drug Abuse, released a report exposing that Purdue Pharma L.P. funded organizations, people, and research to influence the World Health Organization (WHO)’s opioid prescribing recommendations.

The report reveals that two WHO guidelines released in 2011 and 2012 contain dangerously misleading and, in some instances, outright false claims about the safety and efficacy of prescription opioids. Alarmingly, these guidelines mirror Purdue’s marketing strategies to increase prescriptions and expand sales.

The report uncovers that in 2011, the WHO published a guidance document called Ensuring Balance in National Policies on Controlled Substances, Guidance for Availability and Accessibility of Controlled Medicines that, in addition to other falsehoods, repeats Purdue’s disproven claim that dependence occurs in less than one percent of patients.

Then, in 2012, the WHO published a second guidance document called Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses claiming that there is no maximum dosage of strong opioids, like OxyContin, for children. The WHO published this claim despite the fact that U.S. public health agencies had already found that fatal overdoses skyrocket in adult patients who are prescribed above 90 morphine milligram equivalents (MME) per day.

“The web of influence we uncovered paints a picture of a public health organization that has been manipulated by the opioid industry,” said Congresswoman Clark. “The WHO appears to be lending the opioid industry its voice and credibility, and as a result, a trusted public health organization is trafficking dangerous misinformation that could lead to a global opioid epidemic.”

In addition, it appears Purdue was able to insert their marketing strategies into the WHO by creating and funding front organizations, who participated in research that acted as the foundation for the WHO’s guideline documents. The guidelines are widely available and are currently being distributed as public health best practices and reference material for other publications.

In response to their findings, Clark and Rogers published a letter along with the report directed to the WHO. It calls on the WHO to rescind the two guidelines, provide a comprehensive explanation of why the WHO’s internal controls failed to prevent this scheme, and issue a warning to the world that their 2011 and 2012 guidelines should not be followed.

Clark and Rogers were inspired to look into the connections between the opioid industry and the WHO after the WHO failed to respond to a letter sent by the lawmakers in 2017. The letter warned the WHO that Purdue was attempting to expand their drug sales to international markets using the same fraudulent marketing tactics that instigated the opioid crisis in the United States and that if not stopped, Purdue could create a global opioid crisis.

May 20, 2019 News Podcast


Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories: En Banc WCAB Defines “Catastrophic Injury”, California Jury Stunning $2B Cancer Verdict, 44 States Claim 20 Drugmakers Fixed Prices, Jurisdiction Over Home Health Care Limited to UR/IMR, Findings in WCAB Psyche Case Binding in FEHA Claim, LAPD Officer Charged with Comp Fraud, Insurance Agent Allegedly Steals Premiums, USDOL Opposes ABC Employment Test, Comp 83% Combined Ratio Lowest Since 1930s, Opioid Crisis Spreads to Canada and Europe.